共 190 条
[1]
Smith TJ(2015)Recommendations for the use of WBC Growth Factors: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 33 3199-3212
[2]
Bohlke K(2016)Management of febrile neutropaenia: ESMO clinical practice guidelines Ann Oncol 27 v111-v118
[3]
Lyman GH(2011)Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis BMC Cancer 11 404-673
[4]
Carson KR(2014)Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 384 665-193
[5]
Crawford J(2016)A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy Lung Cancer 99 186-1186
[6]
Cross SJ(2016)East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL) Cancer Res Treat 48 1177-4289
[7]
Klastersky J(2013)Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia J Clin Oncol 31 4283-226
[8]
de Naurois J(2009)Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients Tumori 95 219-438
[9]
Rolston K(2017)Cost-effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-Hodgkin lymphoma Pharmacoeconomics 35 425-42
[10]
Rapoport B(2014)Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses J Med Econ 17 32-454